Insights On Drug Discovery

  1. Propelling Glioblastoma Research: Orthotopic Model Solutions 3/27/2025

    Utilize our luciferase-based orthotopic GBM model to accelerate your research on glioblastoma therapies, offering precise tumor monitoring and non-invasive assessment of treatment efficacy.

  2. AI-Powered Digital Pathology For Pulmonary Fibrosis Biomarker Quantification 3/27/2025

    Uncover how AI-driven digital pathology is revolutionizing the detection and quantification of pulmonary fibrosis markers in whole lung sections, offering new opportunities for clinical research.

  3. Thunderstruck By Antibody-Drug Conjugates 3/18/2025

    Antibody-drug conjugates are transforming cancer treatment by targeting tumors directly to reduce side effects. Discover how they affect neighboring cells, which can enhance treatment efficacy and eliminate tumor cell populations.

  4. Smart Scale-Up: Expanding Viral Vectors With Microcarrier Bead Technology 3/12/2025

    Scale up your manufacturing of adherent cell cultures used for viral vector-based treatments with the novel technologies needed to facilitate safe, rapid production.

  5. Innovations In Pregastric Absorption Drug Delivery And ODTs 3/10/2025

    Experts explore permeation enhancers for drug absorption, PBPK modeling for formulation design, and fast-dissolving orally disintegrating tablets (ODTs) shaping drug development.

  6. Discovery And Humanization Of High Affinity Therapeutic Antibodies Against Transmembrane Proteins 2/14/2025

    Here, we present a hybridoma-based antibody discovery and humanization strategy for a T1P target, utilizing Penta Mice immunization to generate monoclonal antibodies.

  7. Elucidating The Role Of IL-18 In NSCLC Integrated Analysis 1/23/2025

    Hear how imaging mass cytometry, CyTOF, and single-cell sequencing unlock the secrets of the tumor microenvironment. Discover new insights into IL-18 and its impact on non-small cell lung cancer.

  8. A Derivatization-Free LCMS Assay For 4β-hydroxycholesterol 1/23/2025

    Learn about a novel LCMS assay for 4β-hydroxycholesterol, a key biomarker for CYP3A activity. This derivatization-free method offers a faster and more efficient approach for clinical studies.

  9. Early Preclinical Development: A Successful Transition To cGMP Manufacturing 12/2/2024

    Explore the development steps that lead to an mRNA construct optimized for your requirements and that meets future-proof cGMP manufacturing requirements, thereby de-risking the development.

  10. Vector Technology For Improved Expression Control Of Biotherapeutic Proteins 11/19/2024

    Discover enhanced vector technology developed to enable better control of expression in cells, enhance titers, and improve expression stability for a range of biotherapeutic formats.